Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

46.20 -0.83 (-1.75%)
Streaming Delayed Price Updated: 12:05 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
40 41 Next >
News headline image
Why Provention Bio Stock Skyrocketed 256% This Week ↗
Provention Bio is currently a partner of Sanofi. It should soon become a part of the big French drugmaker. 
Via The Motley Fool
News headline image
What's Going On With Sanofi Stock After Hours? ↗
Sanofi SA (NASDAQ: SNY) is buzzing in Thursday's after-hours session after the company said it will cut the list price of its most widely prescribed insulin in the United States  
Via Benzinga
News headline image
2 Top Biotech Stocks to Buy Right Now ↗
These two companies are showering shareholders with market-topping payouts. 
Via The Motley Fool
News headline image
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners ↗
On a volatile market day, companies are still looking for smart combinations. 
Via The Motley Fool
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Provention Bio's $2.9B Acquisition - A Strategic Fit For Sanofi ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Sanofi? ↗
 
Via Benzinga
News headline image
Sanofi (NASDAQ: SNY) Set to Acquire Provention Bio (NASDAQ: PRVB) for $2.9 Billion
Provention Bio, Inc. (NASDAQ: PRVB) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development and 
Via Spotlight Growth
News headline image
Pfizer Officially Nabs Seagen For $43 Billion; Provention Soars On Sanofi Deal ↗
Pfizer expects Seagen to add at least $10 billion to its topline in 2030. 
Via Investor's Business Daily
News headline image
Why Provention Bio Stock Is Rocketing Past 52-Week Highs Today ↗
Provention Bio Inc (NASDAQ: PRVB) shares are rocketing higher Monday after Sanofi (NASDAQ: SNY) announced plans to acquire the biopharmaceutical company. 
Via Benzinga
News headline image
Why Is Provention Bio (PRVB) Stock Up 263% Today? ↗
Provention Bio (PRVB) stock is rocketing higher on Monday following news that Sanofi (SNY) is acquiring the company for $2.9 billion. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday! 
Via InvestorPlace
News headline image
FDA Approves Sanofi's Hemophilia A Therapy Offering Significant Bleed Protection ↗
 
Via Benzinga
News headline image
Sanofi (SNY) Q4 2022 Earnings Call Transcript ↗
SNY earnings call for the period ending December 31, 2022. 
Via The Motley Fool
News headline image
Nasdaq Futures Climb Solidly After Past Week's Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows ↗
After the market mayhem seen last week, some semblance of normalcy could return to Wall Street, thanks to the government’s move to assuage concerns in response to the banking crisis. 
Via Benzinga
News headline image
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race ↗
These companies aren't working on a vaccine, but a monoclonal antibody. 
Via Investor's Business Daily
News headline image
7 Blue-Chip Stocks to Buy for Quality-Focused Investors ↗
With circumstances shaky in the market right now, concerned investors may want to consider blue-chip stocks to buy. 
Via InvestorPlace
News headline image
Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval ↗
The French drug company got the nod for a hemophilia treatment. 
Via The Motley Fool
News headline image
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles ↗
 
Via Benzinga
News headline image
Eli Lilly Slashes Insulin Prices By 70%, Will Other Insulin Makers Follow Suit? ↗
Eli Lilly & Co (NYSE: LLY), in an effort to make it easier for patients to access affordable insulin and navigate the complex healthcare system, announced on Wednesday a 70% reduction in the list price... 
Via Benzinga
News headline image
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks ↗
Startling cancer vaccine results from Moderna may point to the next big thing in biotech. 
Via Investor's Business Daily
News headline image
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. 
Via MarketBeat
News headline image
Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees ↗
Shares crumbled after Moderna's flu shot outperformed in just one flu strain. 
Via Investor's Business Daily
News headline image
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review ↗
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
News headline image
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results ↗
Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony... 
Via Benzinga
News headline image
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples ↗
Regeneron beat forecasts despite wide declines. But Sanofi fell on its mixed report. 
Via Investor's Business Daily
News headline image
Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact ↗
Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each... 
Via Benzinga
News headline image
Sanofi Expects Moderate 2023 Profit Growth On Dupixent Demand, But Dampened By Aubagio Generics Competition ↗
 
Via Benzinga
News headline image
Alphabet, Apple And 3 Stocks To Watch Heading Into Friday ↗
With Nasdaq stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
Fear & Greed Index Remains In 'Greed' Zone As Nasdaq Record Sharp Gains For Fourth Straight Week ↗
The CNN Money Fear and Greed index showed some decline in overall sentiment among US investors. US stocks closed mostly higher on Thursday, with the tech-laden Nasdaq index leading the rally. Investors... 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.